Tillotts Pharma AG announces that DIFICLIRTM (fidaxomicin) is recommended for the treatment of Clostridioides difficile infection (CDI) by ESCMID

DIFICLIRTM (fidaxomicin) is now recommended as first-line CDI treatment in both European and U.S. guidelines1,2 Significantly fewer patients in the fidaxomicin group than the vancomycin group

Related Keywords

Japan ,Rheinfelden ,Aargau ,Switzerland ,Tokyo ,United States ,Canada ,United Kingdom ,America ,Mark Wilcox ,Kostenloser Wertpapierhandel ,Van Prehn ,Susi Teichmann ,Tillotts Pharma ,Adrian Hill ,Antimicrob Chemother ,Japanese Zeria Group ,Clinical Study Group ,Society For Healthcare Epidemiology Of America ,Infectious Disease Society Of America ,Leeds Teaching Hospitals University Of ,Head Of International Operations ,Corporate Communications ,European Society Of Clinical Microbiology ,European Centre For Disease Prevention ,First Section Of Tokyo Stock Exchange ,Infectious Diseases Society Of America ,Zeria Pharmaceutical Co Ltd ,European Society ,Clinical Microbiology ,Infectious Diseases ,Infectious Disease Society ,International Operations ,Professor Mark Wilcox ,Medical Microbiology ,Leeds Teaching Hospitals University ,Practice Guideline ,Infectious Diseases Society ,Healthcare Epidemiology ,Update Guidelines ,Clin Infect Dis ,Englj Med ,Disease Prevention ,Infect Control Hosp Epidemiol ,First Section ,Tokyo Stock Exchange ,Manager Corporate Communications ,Tillotts ,Dharma ,Nnounces ,Ificlirtm ,Fidaxomicin ,Ecommended ,Treatment ,Lostridioides ,Difficile ,Infection ,Scmid ,